🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

112 results for “alcohol” Clear

  1. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  2. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  3. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  4. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  5. Oxytocin

    United Therapeutics Europe Ltd

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial

  6. PF-05190457

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial

  7. Placebo

    Pharma Mar S.A.

    Severe Alcohol-Associated Hepatitis

    phase 2 small molecule active

    1 trial

  8. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  9. Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  10. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  11. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  12. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial

  13. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  14. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  15. VK2809

    Viking Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  16. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

  17. Vitamin E

    NORTHWEST BIOTHERAPEUTICS INC

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  18. Zonisamide

    United Therapeutics Europe Ltd

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

  19. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    Novo Nordisk A/S

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  20. varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule completed

    1 trial

  21. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed Pharmaceuticals

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

  22. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  23. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  24. ALN-PNP

    Regeneron UK Limited

    Nonalcoholic Fatty Liver Disease (NAFLD)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources